A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with ...
The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
The Southern District Court of Ohio on Friday heard oral arguments from the federal government and the Chamber of Commerce in the latter’s lawsuit challenging the Medicare Drug Price ...
All of the companies had drugs that made the list of the first 10 medications to be subject to Medicare price negotiations. PhRMA, a leading drug industry trade group, and the US Chamber of ...
Drug companies challenging the law in court could still have several chances to stop the program before next year's election.
“Congress knew that withdrawing all products from federal healthcare programs would be economic suicide—not a ‘real option.’” – U.S. Chamber motion for preliminary injunction On August ...
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short. Merck is suing the federal government over a plan to negotiate Medicare drug ...
The UAW Might Drive the Big Three off a Cliff Democrats Should Not Be So Confident the Biden Impeachment Inquiry Will Be a Bust The Model-Minority ‘Myth’ Is No Myth at All We Need Better ...
Analysis-Drugmakers Could Find Sympathetic US Supreme Court in Drug Pricing Lawsuits By Brendan Pierson (Reuters) - Drugmakers challenging a Biden administration program requiring them to ...
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major ...
Another diabetes drug maker is taking legal action against businesses in several states, alleging that they're "fraudulently ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
